INS and type 1 diabetes mellitus: The study objective is to determine whether daily administration of oral insulin from 4 months to 7 months until the age of 3 years old to children with elevated genetic risk for T1D reduces the cumulative incidence of β-cell autoantibodies and diabetes in childhood.